The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Abstract Introduction Lebrikizumab, a high-affinity IgG4 monoclonal antibody that selectively inhibits interleukin-13 with high binding affinity and slow dissociation rate, prevents the formation of the interleukin-4Rα/interleukin-13Rα1 heterodimer receptor signaling complex. Here we report the impa...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Jennifer Soung, Vivian Laquer, Joseph F. Merola, Angela Moore, Hany Elmaraghy, Chaoran Hu, Maria Lucia Buziqui Piruzeli, Evangeline Pierce, Esther Garcia Gil, Abel D. Jarell
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Adis, Springer Healthcare 2024-07-01
Σειρά:	Dermatology and Therapy
Θέματα:	Atopic dermatitis IL-13 Lebrikizumab MCV Tdap Vaccine response
Διαθέσιμο Online:	https://doi.org/10.1007/s13555-024-01217-w
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!